Pancreatic Cancer
Pancreatic cancer responds to matuzumab augmentation of gemcitabine
Published in Immunotherapy Weekly, June 28th, 2006
"The humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (formerly EMD 72000) is active against pancreatic cancer in preclinical studies. This phase I study assessed the safety and potential benefit of combined treatment with matuzumab and standard-dose gemcitabine," scientists in Germany report.
"Three groups of chemotherapy-naive advanced pancreatic adenocarcinoma patients (n=17) received escalating doses of matuzumab (400 mg weekly, 800 mg biweekly, or 800 mg weekly) and gemcitabine (1000 mgm-2 weekly in weeks 1-3 of each 4-week cycle)....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2006-06-28)
More Articles from Immunotherapy Weekly
- Allergy & Immunology
Earlier introduction of solids could reduce chances of children developing wheat allergies - Allergy & Immunology
T cell receptor codon modification enhances functional expression - Diabetes Therapy
Anti-CD3 and proinsulin therapy enhances remission from diabetes - Rheumatoid Arthritis
Chelsea Therapeutics reports positive clinical results from study of CH-1504 - Simian Immunodeficiency Virus Pathogenesis
IFN-gamma ELISPOT assay measure immune responses in different cell populations - AIDS-Associated Kaposi Sarcoma
AIDS-associated KS prognostic index predicts mortality at initial diagnosis - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
